NextGen Healthcare releases enhancements to EHR-mobile suite

Quality Systems, also known as NextGen Healthcare, have announced product enhancements to their mobile workflow system, including speech documentation for clinic and hospital support and facilitate the management of ICD-10 diagnoses.

NextGen Mobile Suite will now provide clinical documentation support for the hospital setting, allowing providers to switch between inpatient and outpatient cases from a single platform. Additionally, it will also include real-time access to the hospital census list for speech-driven documentation for quicker note-taking.

The suite also provides access to the IMO Problem IT Terminology diagnosis entry tool, allowing users to expedite and simplifying diagnosis codes into electronic health records. The tool has more than 800,000 clinical concepts and 1.8 million synonyms for improved accuracy in physician narrative when inputting data in EHRs.

“Industry dynamics are requiring physicians to be proficient in technology across multiple systems, devices and care settings. Our goal is simple—to provide easy-to-use solutions that allow clinicians to remain focused on delivering quality patient care and practice meaningful medicine,” said Rusty Frantz, President and CEO of NextGen Healthcare. “With these new enhancements, our platform allows physicians, and their entire care team, to remain productive by reducing the administrative burden, ultimately enabling better workflow management across systems, both in the ambulatory and inpatient setting alike.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.